CN107827848A - 一种氧化穿心莲内酯、制备方法及增强cik细胞体内杀伤力的用途 - Google Patents
一种氧化穿心莲内酯、制备方法及增强cik细胞体内杀伤力的用途 Download PDFInfo
- Publication number
- CN107827848A CN107827848A CN201711043501.8A CN201711043501A CN107827848A CN 107827848 A CN107827848 A CN 107827848A CN 201711043501 A CN201711043501 A CN 201711043501A CN 107827848 A CN107827848 A CN 107827848A
- Authority
- CN
- China
- Prior art keywords
- phase
- andrographolide
- oxidation
- ethyl acetate
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 title claims abstract description 75
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 210000004405 cytokine-induced killer cell Anatomy 0.000 title claims abstract description 20
- 231100000225 lethality Toxicity 0.000 title claims abstract description 11
- 238000005728 strengthening Methods 0.000 title claims abstract description 4
- 230000003647 oxidation Effects 0.000 claims abstract description 45
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 45
- 238000006243 chemical reaction Methods 0.000 claims abstract description 37
- 238000000855 fermentation Methods 0.000 claims abstract description 37
- 230000004151 fermentation Effects 0.000 claims abstract description 37
- 239000002608 ionic liquid Substances 0.000 claims abstract description 15
- 238000000605 extraction Methods 0.000 claims abstract description 14
- 244000005700 microbiome Species 0.000 claims abstract description 14
- 238000011534 incubation Methods 0.000 claims abstract description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 75
- 239000002609 medium Substances 0.000 claims description 61
- 239000002904 solvent Substances 0.000 claims description 56
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 52
- 239000000047 product Substances 0.000 claims description 50
- 239000012530 fluid Substances 0.000 claims description 46
- 235000015097 nutrients Nutrition 0.000 claims description 37
- 238000000926 separation method Methods 0.000 claims description 33
- 230000005526 G1 to G0 transition Effects 0.000 claims description 32
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 26
- 239000000706 filtrate Substances 0.000 claims description 24
- 239000001963 growth medium Substances 0.000 claims description 23
- 230000009514 concussion Effects 0.000 claims description 22
- 230000002411 adverse Effects 0.000 claims description 16
- 241000235555 Cunninghamella Species 0.000 claims description 13
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 13
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- 239000002024 ethyl acetate extract Substances 0.000 claims description 12
- 238000001704 evaporation Methods 0.000 claims description 12
- 230000008020 evaporation Effects 0.000 claims description 12
- 239000008103 glucose Substances 0.000 claims description 12
- 238000011081 inoculation Methods 0.000 claims description 12
- 238000009630 liquid culture Methods 0.000 claims description 12
- 235000013575 mashed potatoes Nutrition 0.000 claims description 12
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 12
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 12
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 12
- 238000011084 recovery Methods 0.000 claims description 12
- 238000013517 stratification Methods 0.000 claims description 12
- 235000013343 vitamin Nutrition 0.000 claims description 12
- 229940088594 vitamin Drugs 0.000 claims description 12
- 229930003231 vitamin Natural products 0.000 claims description 12
- 239000011782 vitamin Substances 0.000 claims description 12
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- -1 glyoxaline ion Chemical class 0.000 claims description 6
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims description 5
- 239000012964 benzotriazole Substances 0.000 claims description 5
- 125000002091 cationic group Chemical group 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 238000011426 transformation method Methods 0.000 abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- 238000010262 high-speed countercurrent chromatography Methods 0.000 description 20
- 239000012488 sample solution Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000033228 biological regulation Effects 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 235000019341 magnesium sulphate Nutrition 0.000 description 11
- 238000007872 degassing Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- 239000012046 mixed solvent Substances 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 238000005191 phase separation Methods 0.000 description 10
- 230000006641 stabilisation Effects 0.000 description 10
- 238000011105 stabilization Methods 0.000 description 10
- 238000002604 ultrasonography Methods 0.000 description 10
- 150000002460 imidazoles Chemical class 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 4
- PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical compound C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000370738 Chlorion Species 0.000 description 1
- 241000010216 Cunninghamella blakesleeana Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000012946 outsourcing Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/04—Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
存活率(%) | 占对照组肿瘤重量百分比(%) | |
对照组 | 20 | / |
CIK细胞组 | 65 | 58.8 |
CIK细胞加氧化穿心莲内酯组 | 95 | 25.7 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711043501.8A CN107827848B (zh) | 2017-10-31 | 2017-10-31 | 一种氧化穿心莲内酯、制备方法及增强cik细胞体内杀伤力的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711043501.8A CN107827848B (zh) | 2017-10-31 | 2017-10-31 | 一种氧化穿心莲内酯、制备方法及增强cik细胞体内杀伤力的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107827848A true CN107827848A (zh) | 2018-03-23 |
CN107827848B CN107827848B (zh) | 2021-06-11 |
Family
ID=61650252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711043501.8A Active CN107827848B (zh) | 2017-10-31 | 2017-10-31 | 一种氧化穿心莲内酯、制备方法及增强cik细胞体内杀伤力的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107827848B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110367244A (zh) * | 2019-08-10 | 2019-10-25 | 南京乐扬医药科技有限公司 | 乌药醚内酯用于制备外周血单个核细胞冻存保护剂的用途 |
CN113321631A (zh) * | 2020-08-13 | 2021-08-31 | 云南西力生物技术股份有限公司 | 双穿心莲内酯g及其制备方法和在药物上的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080139622A1 (en) * | 2006-12-11 | 2008-06-12 | Hutchison Medipharma Limited | Decahydronaphthalene Compounds |
CN101200465A (zh) * | 2006-12-11 | 2008-06-18 | 和记黄埔医药(上海)有限公司 | 一种十氢化萘类化合物及其医药用途 |
WO2016065264A1 (en) * | 2014-10-24 | 2016-04-28 | Biogen Ma Inc. | Diterpenoid derivatives and methods of use thereof |
-
2017
- 2017-10-31 CN CN201711043501.8A patent/CN107827848B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080139622A1 (en) * | 2006-12-11 | 2008-06-12 | Hutchison Medipharma Limited | Decahydronaphthalene Compounds |
CN101200465A (zh) * | 2006-12-11 | 2008-06-18 | 和记黄埔医药(上海)有限公司 | 一种十氢化萘类化合物及其医药用途 |
WO2016065264A1 (en) * | 2014-10-24 | 2016-04-28 | Biogen Ma Inc. | Diterpenoid derivatives and methods of use thereof |
Non-Patent Citations (1)
Title |
---|
VIJAYAVITTHAL T. MATHAD ET AL.: "Oxidation studies on Andrographolidey", 《NATURAL PRODUCT RESEARCH》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110367244A (zh) * | 2019-08-10 | 2019-10-25 | 南京乐扬医药科技有限公司 | 乌药醚内酯用于制备外周血单个核细胞冻存保护剂的用途 |
CN113321631A (zh) * | 2020-08-13 | 2021-08-31 | 云南西力生物技术股份有限公司 | 双穿心莲内酯g及其制备方法和在药物上的应用 |
CN113321631B (zh) * | 2020-08-13 | 2022-02-01 | 云南西力生物技术股份有限公司 | 双穿心莲内酯g及其制备方法和在药物上的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN107827848B (zh) | 2021-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105820956B (zh) | 一株牛樟芝菌株及牛樟芝液态发酵方法 | |
CN104473145A (zh) | 一种牛樟芝深层发酵复方制品及其制备方法 | |
CN101376873B (zh) | 一种紫芝发酵方法及制得的紫芝菌丝体 | |
JP6605179B2 (ja) | ラカンカ懸濁細胞中のモグロシドv含有量を高める方法 | |
CN109970538A (zh) | 一类海洋真菌来源的二倍半萜类化合物及其制备方法和在制备抗炎药物中的应用 | |
CN107827848A (zh) | 一种氧化穿心莲内酯、制备方法及增强cik细胞体内杀伤力的用途 | |
CN102674929B (zh) | 一种桦褐孔菌的深层发酵培养基及其深层发酵方法 | |
CN101445815A (zh) | 微生物合成γ-亚麻酸油脂的方法 | |
CN106086147A (zh) | 利用真菌激发子诱导从桦褐孔菌中提取白桦脂酸的方法 | |
CN109680032B (zh) | 一种利用微生物合成7,21-二羟基-20-甲基孕甾-4-烯-3-酮的方法 | |
CN101376904B (zh) | 一种紫芝菌丝体胞内多糖及其制备方法和应用 | |
CN109136112B (zh) | 一种提高蛹虫草菌丝体中虫草素含量的方法 | |
CN102836181B (zh) | 一种樟芝口服液及其制备方法 | |
CN109134574A (zh) | 甾体化合物及其制备方法与应用和抗肿瘤的药物 | |
CN103981104B (zh) | 一株内生真菌及其生物转化甘草酸为甘草次苷的方法 | |
CN105441504B (zh) | 一种环二肽类化合物的制备方法 | |
CN104256575B (zh) | 一种富含叶酸食药真菌发酵产物的制备方法 | |
CN106361780A (zh) | 一种提高樟芝总三萜化合物产量的发酵方法 | |
CN107475321B (zh) | 一种基于微生物转化的脱水穿心莲内酯制备方法 | |
CN109468359A (zh) | 一种人参皂苷Rk6的制备方法 | |
CN104278070A (zh) | 一种提高桑黄液体发酵产物中麦角甾醇含量的方法 | |
CN102093187A (zh) | 聚酮类化合物及其应用 | |
CN107523593B (zh) | 一种微生物发酵制备脱水穿心莲内酯的方法 | |
CN108251490B (zh) | 一种提高液体发酵灵芝菌丝体中灵芝酸a的发酵培养基及发酵方法 | |
CN115215902B (zh) | 一种具有抗炎活性的水溶性红色食用真菌色素及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210527 Address after: Room 801, 238 JIANGCHANG Third Road, Jing'an District, Shanghai 200040 Applicant after: SHANGHAI TAOSHU BIOTECHNOLOGY Co.,Ltd. Address before: 211198 1009 Tianyuan East Road, Gao Xin Garden, Jiangning District, Nanjing, Jiangsu. Applicant before: NANJING XUHANG BIOLOGICAL MATERIAL TECHNOLOGY Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Oxidized andrographolide, preparation method and application of enhancing the lethality of CIK cells in vivo Effective date of registration: 20220901 Granted publication date: 20210611 Pledgee: Bank of Communications Co.,Ltd. Shanghai Jing'an Sub branch Pledgor: SHANGHAI TAOSHU BIOTECHNOLOGY CO.,LTD. Registration number: Y2022310000227 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231122 Granted publication date: 20210611 Pledgee: Bank of Communications Co.,Ltd. Shanghai Jing'an Sub branch Pledgor: SHANGHAI TAOSHU BIOTECHNOLOGY CO.,LTD. Registration number: Y2022310000227 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method for preparing oxidized andrographolide and its application in enhancing the in vivo killing power of CIK cells Effective date of registration: 20231221 Granted publication date: 20210611 Pledgee: Bank of Communications Co.,Ltd. Shanghai Jing'an Sub branch Pledgor: SHANGHAI TAOSHU BIOTECHNOLOGY CO.,LTD. Registration number: Y2023310000902 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |